Quality Assessment of the Clinical Studies on Randomized Controlled Trials of Chinese Herb Medicineand Chemotherapy in the Treatment of Hepatocellular Carcinoma_West China Medical Journal

Authors：

1Department of Integrated Traditional Chinese and Western Medicine,West China Hospital,Sichuan University,Chengdu 610041,China;2Center of Infectious Disease,West China Hospital,Sichuan University,Chengdu 610041,China;

Corresponding author：

Keywords：

肝肿瘤; 栓塞化疗; 中西医结合疗法; Jadad评分量表; CONSORT标准

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

目的：对中药配合肝动脉栓塞化疗（Transcatheter Arterial Chemoembolization,TACE）辅助治疗原发性肝癌随机对照试验(Randomized controlled trial,RCT)文献进行评价。方法：对国内外公开发表的有关中药配合TACE辅助治疗原发性肝癌的随机对照试验进行检索，检索数据库包括Cochrane图书馆临床对照试验库，MEDLINE、CBM、CNKI和VIP电子数据库。手工检索中文相关期刊以及附加检索相关会议论文集。质量评价采用Jadad评分量表、CONSORT标准和其他自拟评价指标进行分析。结果：共纳入103篇RCTs，其中Jadad评分得5分有1篇文献，3分1篇，2分10篇，71篇1分，其余20篇均为0分，有3篇文献报告了分配隐藏。按CONSORT标准，仅1篇(0.97%)RCT描述了如何产生随机顺序，没有RCT报道如何执行随机，其中1篇为半随机，有1篇(0.97%)RCT采用安慰剂对照，有54篇(52.43%)报道了终点指标，分别各有2篇(1.94%)报道了双盲和单盲，14篇(1359%)进行了具体统计量计算，54篇(52.43%)提供了随访记录，7篇(6.80%)报道了阴性结果，16篇(15.53%)报道不良事件，仅有1篇(0.97%)进行样本含量计算与意向性分析(ITT),有2篇(1.94%)进行分层分析，属于多中心的仅有1篇(0.97%)，均未进行伦理审批和知情同意。描述了中医证型的有3篇(2.91%)。结论:目前中药配合TACE辅助治疗原发性肝癌临床研究的方法学和报告质量尚低，且多数RCT可能存在选择性偏倚和测量性偏倚，期待更多高质量的随机双盲对照试验为临床应用提供可靠的依据。

Citation： MENG Maobin,WANG Gang,CUI Yaoli,et al.. Quality Assessment of the Clinical Studies on Randomized Controlled Trials of Chinese Herb Medicineand Chemotherapy in the Treatment of Hepatocellular Carcinoma. West China Medical Journal, 2008, 23(1): 1-2. doi: Copy

1.
2.
3.	[3]Pisani P,Parkin M,Bray F,et al.Estimates of the worldwide mortality from 25 cancers in 1990[J].Int J Cancer,1999,83:18-29.
4.	[4]Chun-Jen Liu,Jia-Horng Kao,et al.Hepatitis B Virus-related Hepatocellular Carcinoma:Epidemiology and Pathogenic Role of Viral Factors [J].J Chin Med Assoc.2007,70(4):141-145.
5.	[5]Mathurin P,Rixe O,Carbonell N,et al.Review artice:overview of medical treatment in unresectable hepatocellular carcinoma-an impossible meta-analysis[J]? Aliment Pharmacol Ther,1998，12:111.
6.	[6]Katsushima S,Inokuna T,Oi H,et al.Acute hepatic failure following transcatheter arterial embolization for the treatment of hepa.
7.
8.	tocellular carcinoma [J].Digestion,1997,58:189.
9.	[7]Jadad AR,Moore RA,Carroll D,Jenkinson C,ReynoldsDJM,Gavaghan DJ,McQuay HJ.Assessing the quality of reports of randomized trials:Is.
10.
11.	blinding necessary[J]?Controlled Clin Trials,1996，17(1):1-12.
12.	[8]David Moher K F S,D G A,CONSORT Group.The CONSORT statement:revised recommendation for improving the quality of reports of parallel.
13.
14.	group randomized trials[J].Chinese J Evidence-Based Medicine,2005,5(9):702-707.
15.	[9]Genais SD,Tricco AC,卞兆祥等.中草药临床研究的评价[J].中西医结合学报， 2006,4(5):455-466.
16.	[10]Moher D,Soeken K,Sampson M,et al.Assessing the quality of reports of systematic reviews in pediatric complementary and alternative medicine[J].BMC Pediatr.2002，2:3.
17.	[11]Gang W,Bing M,Ze-Yu X,et al.The quality of reporting of randomized controlled trials of Traditional Chinese Medicine:A survey of 13 randomly selected journal from Mainland China[J].Clin Therapeutics.2007，29(7):1456-1467.
18.	[12]Peng XX,Zhao YL,Liang XY,et al.Assessing the Quality of RCTs on the effect of β-elemene,one ingredient of a Chinese herb,against malignant tumor[J].C.
19.
20.	ontemp Clin Trials,2006,27:70-82.
21.	[13]李静.随机分配方案的隐藏[J].中国循证医学杂志，2004,4(10):714-715.
22.	[14]Mills EJ,Wu P,Gagnier J,et al.The qual ity of randomized trial reporting in leading medical journals since the revised CONSORT statement[J].Contemp.
23.
24.	Clin Trials,2005,26(4):480-487.
25.	[15]Schulz KF,Chalmers I,Hayes RJ,et al.Empirical evidence of bias:dimensions of methodological qual ity associated with estimates of effects of controller.
26.
27.	trials[J].JAMA,1995,273(5):408-412.
28.	[16]Llorca J,Martinez SF,Prieto SD,et al.Qual ity of controlled cl inical trials on glaucoma and intraocular high pressure[J].J Glaucoma,2005,14(3):190-19.
29.
30.	American Cancer Society:Cancer Facts and Figures 2007.Available from http://www.cancer.org/docroot/home/index.asp.
31.	Ministry of health of the people republic of China:Retrospective Sampling Survey on Malignant Tumor in China from 1990 to 1992.Available from http://www.moh.gov.cn/open/statistics/digest04/s78.htm.
32.	.

1.
2.
3. [3]Pisani P,Parkin M,Bray F,et al.Estimates of the worldwide mortality from 25 cancers in 1990[J].Int J Cancer,1999,83:18-29.
4. [4]Chun-Jen Liu,Jia-Horng Kao,et al.Hepatitis B Virus-related Hepatocellular Carcinoma:Epidemiology and Pathogenic Role of Viral Factors [J].J Chin Med Assoc.2007,70(4):141-145.
5. [5]Mathurin P,Rixe O,Carbonell N,et al.Review artice:overview of medical treatment in unresectable hepatocellular carcinoma-an impossible meta-analysis[J]? Aliment Pharmacol Ther,1998，12:111.
6. [6]Katsushima S,Inokuna T,Oi H,et al.Acute hepatic failure following transcatheter arterial embolization for the treatment of hepa.
7.
8. tocellular carcinoma [J].Digestion,1997,58:189.
9. [7]Jadad AR,Moore RA,Carroll D,Jenkinson C,ReynoldsDJM,Gavaghan DJ,McQuay HJ.Assessing the quality of reports of randomized trials:Is.
10.
11. blinding necessary[J]?Controlled Clin Trials,1996，17(1):1-12.
12. [8]David Moher K F S,D G A,CONSORT Group.The CONSORT statement:revised recommendation for improving the quality of reports of parallel.
13.
14. group randomized trials[J].Chinese J Evidence-Based Medicine,2005,5(9):702-707.
15. [9]Genais SD,Tricco AC,卞兆祥等.中草药临床研究的评价[J].中西医结合学报， 2006,4(5):455-466.
16. [10]Moher D,Soeken K,Sampson M,et al.Assessing the quality of reports of systematic reviews in pediatric complementary and alternative medicine[J].BMC Pediatr.2002，2:3.
17. [11]Gang W,Bing M,Ze-Yu X,et al.The quality of reporting of randomized controlled trials of Traditional Chinese Medicine:A survey of 13 randomly selected journal from Mainland China[J].Clin Therapeutics.2007，29(7):1456-1467.
18. [12]Peng XX,Zhao YL,Liang XY,et al.Assessing the Quality of RCTs on the effect of β-elemene,one ingredient of a Chinese herb,against malignant tumor[J].C.
19.
20. ontemp Clin Trials,2006,27:70-82.
21. [13]李静.随机分配方案的隐藏[J].中国循证医学杂志，2004,4(10):714-715.
22. [14]Mills EJ,Wu P,Gagnier J,et al.The qual ity of randomized trial reporting in leading medical journals since the revised CONSORT statement[J].Contemp.
23.
24. Clin Trials,2005,26(4):480-487.
25. [15]Schulz KF,Chalmers I,Hayes RJ,et al.Empirical evidence of bias:dimensions of methodological qual ity associated with estimates of effects of controller.
26.
27. trials[J].JAMA,1995,273(5):408-412.
28. [16]Llorca J,Martinez SF,Prieto SD,et al.Qual ity of controlled cl inical trials on glaucoma and intraocular high pressure[J].J Glaucoma,2005,14(3):190-19.
29.
30. American Cancer Society:Cancer Facts and Figures 2007.Available from http://www.cancer.org/docroot/home/index.asp.
31. Ministry of health of the people republic of China:Retrospective Sampling Survey on Malignant Tumor in China from 1990 to 1992.Available from http://www.moh.gov.cn/open/statistics/digest04/s78.htm.
32. .

West China Medical Journal

Quality Assessment of the Clinical Studies on Randomized Controlled Trials of Chinese Herb Medicineand Chemotherapy in the Treatment of Hepatocellular Carcinoma

Abstract Full text Figures/Tables Video References Cited by

Format

Content